Every 424B that Genelux Corporation (GNLX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GNLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNLX filings page.
Genelux has filed a prospectus supplement to sell up to $100,000,000 of its common stock through an "at-the-market" program with TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on Nasdaq or other trading venues at market prices; TD Cowen may be paid commissions of up to 3.0% of gross proceeds.
The supplement states assumed illustrative math based on a $2.59 per‑share price, showing up to 76,749,183 shares outstanding after sales (based on 38,139,144 shares outstanding as of December 31, 2025). Net proceeds are for general corporate purposes, including research, development, clinical trials, capital expenditures and working capital.
Genelux Corporation is offering 6,666,667 shares of common stock at $3.00 per share in an underwritten Nasdaq offering. The company expects net proceeds of approximately $18.3 million, or about $21.1 million if the underwriters fully exercise their 1,000,000-share option, after underwriting discounts and expenses. Shares outstanding are expected to rise to 44,713,445, or 45,713,445 if the option is fully exercised, which will dilute new investors compared with the $0.82 pro forma net tangible book value per share. Genelux plans to use the cash for general corporate purposes, including research and development, clinical trials, capital spending and working capital, and believes that, together with existing resources, this funding will support operations for at least 12 months. The prospectus also highlights interim clinical data for Olvi-Vec in lung cancer trials and notes a prior auditor going concern explanatory paragraph.
Genelux Corporation plans a primary offering of common stock under its shelf registration, with Lucid Capital Markets as sole book‑runner. The company expects to use the net proceeds for general corporate purposes, including research and development, clinical trial expenses, capital expenditures and working capital, and may also in‑license or acquire complementary assets.
Genelux is a late clinical‑stage biopharmaceutical company developing oncolytic viral immunotherapies, led by its Olvi‑Vec product candidate. Recent interim data in small cell lung cancer showed 9 evaluable patients with a 33% overall response rate and signs of durability, and in non‑small cell lung cancer 5 evaluable patients with a 60% disease control rate and tumor shrinkage in several patients.
The company highlights that its auditor’s report includes an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern, and it warns investors about immediate and potential future dilution, significant stock price volatility, lack of dividends, and broad discretion over use of proceeds.